Effect of sodium tanshinoneⅡA sulfonate combined with atorvastatin on plasma endothelin and brain natriuretic in patients with coronary heart diseases

doi:10.3969/j.issn.1002-7386.2015.22.006

Abstract：Objective To investigate the role of plasma endothelin (ET-1) and brain natriuretic (BNP) in coronary heart diseases (CHD), and to analyze the effects of sodium tanshinone ⅡA sulfonate combined with atorvastatin on the expression levels of ET-1 and BNP.Methods One hundred and sixty patients with CHD who were diagnosed and treated in our hospital were randomly divided into observation group A ( n =80) and observation group B ( n =80),at the same time, 100 healthy subjects were served as control group.The plasma levels of ET-1 and BNP were detected by radioimmunoassay and enzyme-linked immunosorbent assay (ELISA),respectively.The 80 patients in observation group A,on the basis of routine therapy,were treated by atorvastatin,however,the other 80 patients in observation group B,on the basis of observation group A, were treated by sodium tanshinone ⅡA sulfonate injection, with a treatment course of 30 days for both groups.The left ventricular ejection fraction (LVEF), left ventricular internal dimension at end-systolic (LVESD),left ventricular internal dimension at end-diastole ( LVEDD) ,plasma levels of ET-1 and BNP were detected before and after treatment,meanwhile, the improvement status of life quality of patients was compared between two groups.Results The plasma levels of ET-1 and BNP in CHD groups were significantly increased,as compared with those in control group ( P <0.05),moreover, the plasma levels of ET-1 and BNP were gradually increased with the increasing of grading of cardiac function and severe degree of of coronary artery lesions ( P <0.05).The plasma levels of ET-1 and BNP were positively correlated to cardiac function and severe degree of of coronary artery lesions ( P <0.05).As compared with those before treatment, the plasma levels of ET-1 and BNP were significant decreased after treatment in both observation groups ( P <0.05) ,furthermore, the decreasing degree in observation group B was more obvious than that in observation group A ( P <0.05).In addition, the improvement degree of life quality of patients in observation group B was superior to that in observation group A ( P <0.05).Conclusion Sodium tanshinoneⅡA sulfonate combined with atorvastatin can effectively improve cardiac function of patients with CHD, and its action mechanism may be correlated to reducing the plasma levels of ET-1 and BNP.